1997年,羊毒素A(LAN)在中国引入。它现在在亚洲可用,拉丁美洲和东欧的各种品牌,包括恒力®,Lantox®,Prosigne®,Lanzox®,Redux®,Liftox®,HBTX-A和CBTX-A关于局域网的文献大多以中文出版,限制其国际可获得性。我们,因此,希望生成所有LAN出版物的完整英文参考书目,然后将其用于全面的正式文献综述。总之,从PubMed和科学技术论文引文数据库检索到379篇LAN出版物(中文322篇,英文57篇)。所涵盖的指示是电机(257),腺体(16),疼痛(32)和美学(48)。主题是神经学(250),美学(48),儿科(38),眼科(18),泌尿外科(9),方法论(6),胃肠病学(5),耳朵,鼻子和喉咙(4)和手术(1)。71篇出版物是随机对照试验,41份出版物是介入性研究和观察性研究,15种出版物是案例研究,十八种出版物是评论,和两个出版物是指导方针。LAN出版物涵盖了20多年来BT治疗的所有相关主题。这构成了类似于其他BT药物的出版基础。没有一个LAN出版物提供与其他BTA型药物产生的数据相矛盾的数据。当使用1:1的LAN-烟草素A转化率与烟草素A相比时,LAN似乎具有相似的功效和安全性特征。对于LAN在欧洲和北美的注册,大型受控多中心研究将成为必要。
In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin America and Eastern Europe under various brand names including Hengli®, Lantox®, Prosigne®, Lanzox®, Redux®, Liftox®, HBTX-A and CBTX-A. The literature on LAN is mostly published in Chinese language, restricting its international accessibility. We, therefore, wanted to generate a complete English bibliography of all LAN publications and then use it for a comprehensive formalised literature review. Altogether, 379 LAN publications (322 in Chinese and 57 in English) were retrieved from PubMed and Science and Technology Paper Citation Database. Indications covered are motor (257), glandular (16), pain (32) and aesthetics (48). Topics are neurological (250), aesthetic (48), paediatric (38), ophthalmological (18), urological (9), methodological (6), gastroenterological (5), ear, nose and throat (4) and surgical (1). Seventy-one publications are randomised controlled trials, forty-one publications are interventional studies and observational studies, fifteen publications are case studies, eighteen publications are reviews, and two publications are guidelines. LAN publications cover all relevant topics of BT therapy throughout a period of more than 20 years. This constitutes a publication basis resembling those of other BT drugs. None of the LAN publications presents data contradictory to those generated with other BT type-A drugs. LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN- onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN\'s registrations in Europe and North America.